EDUARDO MURACCA YOSHINAGA
Índice h a partir de 2011
7
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
conferenceObject LONG-TERM EVALUATION OF TRANSURETHRAL INCISION OF THE PROSTATE FOR TREATMENT OF BENIGN PROSTATE HYPERPLASIA: ANALYSIS OF 75 CASES WITH A MEAN 8-YEAR FOLLOW-UP PERIOD(2015) CORDEIRO, Paulo; BARONE, Hugo; YOSHINAGA, Eduardo Muracca; NAKANO, Elcio; NAHAS, William C.; SROUGI, Miguel; ANTUNES, Alberto A.conferenceObject LOW-VOLUME PROSTATE IN BENIGN PROSTATIC HYPERPLASIA (BPH): A RISK FACTOR FOR SYMPTOMATIC BLADDER DIVERTICULA REQUIRING SURGICAL TREATMENT(2015) YOSHINAGA, Eduardo Muracca; NAKANO, Elcio; MARCHINI, Giovanni S.; OYAMA, Renato Hajime; CORDEIRO, Paulo; NAHAS, William C.; SROUGI, Miguel; ANTUNES, Alberto A.conferenceObject THE PAINFUL PELVIC SYMPTOMS IN AGING MEN. THE RESULTS OF POPULATION-BASED SAMPLE OF MEN(2016) NAKANO, Elcio; CONTI, Paulo Sajovic de; YOSHINAGA, Eduardo Muracca; NAHAS, William C.; SROUGI, Miguel; ANTUNES, Alberto- Prostatic Artery Embolization for Treatment of Benign Prostatic Hyperplasia in Patients with Prostates > 90 g: A Prospective Single-Center Study(2015) ASSIS, Andre Moreira de; MOREIRA, Airton Mota; RODRIGUES, Vanessa Cristina de Paula; YOSHINAGA, Eduardo Muracca; ANTUNES, Alberto Azoubel; HARWARD, Sardis Honoria; SROUGI, Miguel; CARNEVALE, Francisco CesarPurpose: To describe the safety and efficacy of prostatic artery embolization (PAE) with spherical microparticles to treat lower urinary tract symptoms associated with benign prostatic hyperplasia in patients with prostate volume > 90 g. Materials and Methods: This prospective, single-center, single-arm study was conducted in 35 patients with prostate volumes ranging from 90-252 g. Mean patient age was 64.8 years (range, 53-77 y). Magnetic resonance imaging, uroflowmetry, and the International Prostate Symptom Score (IPSS) were used to assess clinical and functional outcomes. Results: Mean prostate size decreased significantly from 135.1 g before PAE to 91.9 g at 3 months of follow-up (P < .0001). Mean IPSS and quality-of-life index improved from 18.3 to 2.7 and 4.8 to 0.9 (P < .0001 for both), respectively. A significant negative conelation was observed between prostate-specific antigen at 24 hours after PAE and IPSS 3 months after PAE (P = .0057). Conclusions: PAE is a safe and effective treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia in patients with prostate volume > 90 g. Excessively elevated prostate-specific antigen within 24 hours of PAE is associated with; lower symptom burden in short-term follow-up.